NHSA Releases 2026 NRDL Update Adding 107 Drugs Including Million‑Yuan CAR‑T Therapies – Ninth List Adjustment Since the Agency’s Establishment
China's National Healthcare Security Administration (NHSA) released the National Drug List for Basic Medical Insurance, Maternity Insurance, and Work‑Related Injury Insurance (NRDL) and the Commercial Health Insurance Innovative Drug List…
MindRank and BoomRay Forge Strategic Alliance to Build AI‑Driven Radioligand Conjugates – Cyclic Peptide RDCs Target First‑in‑Class Oncology Assets
Hangzhou MindRank Technology Co., Ltd. and Suzhou BoomRay Pharma Co., Ltd. announced a strategic collaboration to jointly develop AI‑driven radioligand conjugate (RDC) drugs that use cyclic peptides as targeting ligands, addressing unmet needs in precision oncology diagnostics and therapeutics and…
Where biopharma's biggest deals take shape!
Fosun Pharma Presents Mixed Phase III POLARIS‑AD Topline Data for Oral AR1001 in Early Alzheimer’s Disease at CTAD 2026 – Monotherapy Population Meets Primary CDR‑SB Endpoint
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) announced that topline results from the global, multicenter Phase III POLARIS‑AD trial of the oral investigational drug AR1001 for early…
NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs
The Comprehensive Department of China's National Medical Products Administration (NMPA) has released the Measures for the Implementation of Drug Market Exclusivity (Draft for Comment), proposing a unified exclusivity regime that…
